Journal ArticleDOI
Minimally invasive surgical aortic valve replacement versus transfemoral transcatheter aortic valve implantation in low-risk octogenarians : Observational, retrospective and single-center study.
TLDR
The present study on low-risk octogenarians, transfemoral TAVI and minimally invasive AVR showed comparable short-term and mid-term results, and both procedures are deemed safe and effective.About:
This article is published in Wiener klinische Wochenschrift.The article was published on 2022-10-14. It has received 0 citations till now. The article focuses on the topics: Medicine & Medicine.read more
References
More filters
Journal ArticleDOI
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.
Martin B. Leon,Craig R. Smith,Michael J. Mack,Michael J. Mack,Rajendra Makkar,Lars G. Svensson,Susheel Kodali,Vinod H. Thourani,Murat Tuzcu,D. Craig Miller,Howard C. Herrmann,Darshan Doshi,David J. Cohen,Augusto D. Pichard,Samir R. Kapadia,Todd M. Dewey,Vasilis Babaliaros,Wilson Y. Szeto,Mathew R. Williams,Dean J. Kereiakes,Alan Zajarias,Kevin L. Greason,Brian Whisenant,Robert W. Hodson,Jeffrey W. Moses,Alfredo Trento,David L. Brown,William F. Fearon,Philippe Pibarot,Rebecca T. Hahn,Wael A. Jaber,William N. Anderson,Maria Alu,John G. Webb +33 more
TL;DR: In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke; surgery resulted in fewer major vascular complications and less paravalvular aorta regurgitation.
Journal ArticleDOI
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
Michael J. Mack,Martin B. Leon,Vinod H. Thourani,Raj Makkar,Susheel Kodali,Mark J. Russo,Samir R. Kapadia,S. Chris Malaisrie,David J. Cohen,Philippe Pibarot,Jonathon Leipsic,Rebecca T. Hahn,Philipp Blanke,Mathew R. Williams,James M. McCabe,David L. Brown,Vasilis Babaliaros,Scott M. Goldman,Wilson Y. Szeto,Philippe Généreux,Ashish Pershad,Stuart J. Pocock,Maria Alu,John G. Webb,Craig R. Smith +24 more
TL;DR: Among patients with severe aortic stenosis who were at low surgical risk, the rate of the composite of death, stroke, or rehospitalization at 1 year was significantly lower with TAVR than with surgery.
Journal ArticleDOI
Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients
Jeffrey J. Popma,G. Michael Deeb,Steven J. Yakubov,Mubashir Mumtaz,Hemal Gada,Daniel O'Hair,Tanvir Bajwa,John Heiser,William Merhi,Neal S. Kleiman,Judah Askew,Paul Sorajja,Joshua Rovin,Stanley Chetcuti,David H. Adams,P.S. Teirstein,George L. Zorn,John K. Forrest,Didier Tchetche,Jon R. Resar,Antony Walton,Nicolo Piazza,Basel Ramlawi,Newell Robinson,George Petrossian,Thomas G. Gleason,Jae K. Oh,Michael J. Boulware,Hongyan Qiao,Andrew S. Mugglin,Michael J. Reardon +30 more
TL;DR: In patients with severe aortic stenosis who were at low surgical risk, TAVR with a self‐expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months.
Journal ArticleDOI
Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
Michael J. Reardon,N. M. Van Mieghem,Jeffrey J. Popma,Neal S. Kleiman,Lars Søndergaard,Mubashir Mumtaz,David H. Adams,G. M. Deeb,Brijeshwar Maini,Hemal Gada,Stanley Chetcuti,Thomas G. Gleason,John Heiser,Ruediger Lange,William Merhi,Jae Oh,Peter Skov Olsen,Nicolo Piazza,M. Williams,Stephan Windecker,Steven J. Yakubov,Eberhard Grube,Raj Makkar,Jonathan S. Lee,John V. Conte,E. Vang,Hang Nguyen,Yanping Chang,Andrew S. Mugglin,Patrick W. Serruys,Arie-Pieter Kappetein +30 more
TL;DR: TAVR was a noninferior alternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, with a different pattern of adverse events associated with each procedure.
Journal ArticleDOI
Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement
Susheel Kodali,Mathew R. Williams,Craig R. Smith,Lars G. Svensson,John G. Webb,Raj Makkar,Gregory P. Fontana,Todd M. Dewey,Vinod H. Thourani,Augusto D. Pichard,Michael P. Fischbein,Wilson Y. Szeto,Scott Lim,Kevin L. Greason,Paul S. Teirstein,S. Chris Malaisrie,Pamela S. Douglas,Rebecca T. Hahn,Brian Whisenant,Alan Zajarias,Duolao Wang,Jodi J. Akin,William N. Anderson,Martin B. Leon,Trial Investigators +24 more
TL;DR: A 2-year follow-up of patients in the PARTNER trial supports TAVR as an alternative to surgery in high-risk patients, but paravalvular regurgitation was more frequent after T AVR and was associated with increased late mortality.